From DCAT Value Chain Insights (VCI)
CordenPharma, a contract development and manufacturing organization of drug substances and drug products, has completed an early-development suite for highly potent, oral solid dosage products at its site in Plankstadt, Germany. The new facility allows for the production of small batches, from 100 g to approximately 1,000 g.
CordenPharma Plankstadt’s setup has engineering controls to allow for the production of compounds with various potencies and degrees of containment. All steps can be performed, starting from dispensing to film coating, in an engineering controlled environment. CordenPharma Plankstadt, located near Heidelberg, Germany, provides development and manufacturing of solid dosage forms, specializing in the safe handling of highly potent active pharmaceutical ingredients and drug products.
The investment in CordenPharma Plankstadt is the latest of several announced investments made by CordenPharma during 2017, where further capacity expansion and capabilities were installed in CordenPharma Colorado and CordenPharma Plankstadt.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription